What is Roth Capital’s Forecast for GeoVax Labs Q1 Earnings?

GeoVax Labs, Inc. (NASDAQ:GOVX) – Investment analysts at Roth Capital issued their Q1 2025 earnings estimates for shares of GeoVax Labs in a research note issued on Tuesday, November 12th. Roth Capital analyst J. Aschoff forecasts that the company will earn ($0.36) per share for the quarter. The consensus estimate for GeoVax Labs’ current full-year earnings is ($5.10) per share. Roth Capital also issued estimates for GeoVax Labs’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.18) EPS.

A number of other analysts have also weighed in on GOVX. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a research note on Monday, August 12th. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Alliance Global Partners assumed coverage on shares of GeoVax Labs in a report on Monday. They set a “buy” rating and a $15.00 price target on the stock. Finally, Noble Financial increased their price target on shares of GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, August 19th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $13.25.

GeoVax Labs Trading Down 3.3 %

NASDAQ:GOVX opened at $2.61 on Thursday. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18. The company’s fifty day moving average price is $2.42 and its 200-day moving average price is $2.59.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.38. The firm had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same quarter last year, the firm earned ($4.80) EPS.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.